I also have a single APOE4 allele. I am lean and fit with no metabolic or other heath problems. I microdosed Tirzepatide for a year at the rate of .6 mg per week as an uncontrolled n = 1 experiment. I wanted to see if this protocol would change any of my blood biomarkers. It did not. At such a low dose, it had, as far as I could tell, no effect whatsoever on me. I didn’t lose weight and didn’t lose lean mass. I got tired of the weekly injection so recently stopped taking it. All that said, my understanding is that, in the observational data on people with a metabolic disease who take GLP-1 drugs, the rates of other diseases such as dementia seem to decrease more than can be accounted for by weight loss alone. I am, of course, externally skeptical of extrapolations from observational studies - they rarely survive the rigors of a randomized controlled trial - but I think that this is the bet that metabolically healthy people who microdose GLP-1s are taking: that the drug may reduce the incidence of diseases like heart disease and dementia by mechanisms other than weight loss, and that these mechanisms may also work at low doses in metabolically healthy people.
Focus on high quality protein at each meal, such as fish, eggs, dairy, poultry, lean meat, soy, beans, and lentils. For most middle aged and older adults who strength train, consistency and food quality matter more than an exact gram target.
I also have a single APOE4 allele. I am lean and fit with no metabolic or other heath problems. I microdosed Tirzepatide for a year at the rate of .6 mg per week as an uncontrolled n = 1 experiment. I wanted to see if this protocol would change any of my blood biomarkers. It did not. At such a low dose, it had, as far as I could tell, no effect whatsoever on me. I didn’t lose weight and didn’t lose lean mass. I got tired of the weekly injection so recently stopped taking it. All that said, my understanding is that, in the observational data on people with a metabolic disease who take GLP-1 drugs, the rates of other diseases such as dementia seem to decrease more than can be accounted for by weight loss alone. I am, of course, externally skeptical of extrapolations from observational studies - they rarely survive the rigors of a randomized controlled trial - but I think that this is the bet that metabolically healthy people who microdose GLP-1s are taking: that the drug may reduce the incidence of diseases like heart disease and dementia by mechanisms other than weight loss, and that these mechanisms may also work at low doses in metabolically healthy people.
How do you define “adequate protein “ for a middle aged or older adult who strength trains?
Focus on high quality protein at each meal, such as fish, eggs, dairy, poultry, lean meat, soy, beans, and lentils. For most middle aged and older adults who strength train, consistency and food quality matter more than an exact gram target.